Challenges for PEGylated proteins and alternative half-life extension technologies based on biodegradable polymers

ACS Symposium Series

Volumn 1135, Issue , 2013, Pages 215-233

  Besheer, Ahmed ^a   Liebner, Robert ^a   Meyer, Martin ^b   Winter, Gerhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Fresenius Kabi Deutschland GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUNCTIONAL POLYMERS; MEDICAL APPLICATIONS; MOLECULES; SCAFFOLDS (BIOLOGY);

ANTIBODY FRAGMENT; CONCENTRATED SOLUTION; PEGYLATED PROTEINS; POLYETHYLENE GLYCOL (PEG); PROTEIN BINDERS; PROTEIN SCAFFOLDS; SMALL MOLECULES; THERAPEUTIC MOLECULES;

PROTEINS;

EID: 84905367745     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2013-1135.ch013     Document Type: Conference Paper

References (80)

1. Walsh, G. Nat. Biotechnol. 2010, 28 (9), 917-924.
2. R&D Pipeline News, Top 30 Biologics 2010; www. pipelinereview. com 2011 (accessed 06.11.2012).
3. Abuchowski, A.; van Es, T.; Palczuk, N. C.; Davis, F. F. J. Biol. Chem. 1977, 252 (11), 3578-3581.
4. Abuchowski, A.; McCoy, J. R.; Palczuk, N. C.; van Es, T.; Davis, F. F. J. Biol. Chem. 1977, 252 (11), 3582-3586.
5. Veronese, F. M.; Pasut, G. Drug Discovery Today 2005, 10 (21), 1451-1458.
6. Veronese, F. M.; Mero, A.; Pasut, G. In PEGylated protein drugs: Basic science and clinical applications; Veronese, F. M., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2009; p 113.
7. Pammolli, F.; Magazzini, L.; Riccaboni, M. Nat. Rev. Drug Discovery 2011, 10, 428-438.
8. Aggarwal, S. Nat. Biotechnol. 2011, 29 (12), 1083-1089.
9. Sheridan, C. Nat. Biotechnol. 2007, 25 (4), 365-366.
10. Moran, N. Nat. Biotechnol. 2011, 29 (1), 5-6.
11. Skerra, A. Curr. Opin. Biotechnol. 2007, 18, 295-304.
12. Kontermann, R. E. BioDrugs 2009, 23 (2), 93-109.
13. Chen, J.; Spear, S. K.; Huddleston, J. G.; Rogers, R. D. Green Chem. 2005, 7 (2), 64-82.
14. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. Angew. Chem., Int. Ed. 2010, 49 (36), 6288-6308.
15. Israelachvili, J. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 8378.
16. Wattendorf, U.; Merkle, H. P. J. Pharm. Sci. 2008, 97 (11), 4655-4669.
17. Begum, R.; Matsuura, H. J. Chem. Soc., Faraday Trans. 1997, 93 (21), 3839-3848.
18. Kirincic, S.; Klofutar, C. Fluid Phase Equilib. 1999, 155, 311-325.
19. Ninni, L.; Burd, H.; Fung, W. H.; Meirelles, A. J. A. J. Chem. Eng. Data 2003, 48, 324-329.
20. Eugene, M. Cell Mol. Biol. 2004, 50 (3), 209-215.
21. Zalavsky, B. Y. Aqueous two-phase partitioning: Physical chemistry and bioanalytical applications; Marcel Dekker, Inc.: New York, 1995.
22. Asgeirsson, D.; Venturoli, D.; Fries, E.; Rippe, B.; Rippe, C. Acta Physiol. 2007, 191 (3), 237-246.
23. Kerwin, B. A.; Chang, B. S.; Gegg, C. V.; Gonnelli, M.; Li, T. S.; Strambini, G. B. Protein Sci. 2002, 11 (7), 1825-1833.
24. Bailon, P.; Berthold, W. Pharm. Sci. Technol. Today 1988, 1 (8), 352-356.
25. Bailon, P.; Won, C. Y. Expert Opin. Drug Delivery 2009, 6 (1), 1-16.
26. Yowell, S. L.; Blackwell, S. Cancer Treat Rev. 2002, 28 (Suppl A), 3-6.
27. Veronese, F. M. Biomaterials 2001, 22, 405-417.
28. Payne, R. W.; Murphy, B. M.; Manning, M. C. Pharm. Dev. Technol. 2010, 1-18.
29. Kumar, V.; Kalonia, D. S. AAPS PharmSciTech 2006, 7 (3), 62.
30. Seely, J.; Buckel, S. D.; Green, P. D.; Richey, C. BioPharm Int. 2005.
31. Zhang, B.; Towers, E. W.; Poppe, L.; Cockrill, S. L. J. Pharm. Sci. 2011.
32. Chin, H.-W.; Gikanga, B.; Yang, Y.; Zhang, B. J. Pharm. Sci. 2011, 100 (7), 2518-2525.
33. Lee, B. L.; Kwon, J. S.; Kim, H. J.; Yamamoto, S.; Lee, E. K. Solid-Phase Bioconjugate Chem. 2007, 18, 1728-1734.
34. Viegas, T. X.; Veronese, F. M. In PEGylated protein drugs: Basic science and clinical applications; Veronese, F. M., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2009; p 113.
35. Chi, E. Y.; Krishnan, S.; Kendrick, B. S.; Chang, B. S.; Carpenter, J. F.; Randolph, T. W. Protein Sci. 2003, 12 (5), 903-913.
36. Rodriguez-Martinez, J. A.; Sola, R. J.; Castillo, B.; Cintron-Colon, H. R.; Rivera-Rivera, I.; Barletta, G.; Griebenow, K. Biotechnol. Bioeng. 2008, 101 (6), 1142-1149.
37. Nie, Y.; Zhang, X.; Wang, X.; Chen, J. Bioconjugate Chem. 2006, 17 (4), 995-999.
38. Gonnelli, M.; Strambini, G. B. Biochim. Biophys. Acta 2009, 1794, 569-576.
39. Basu, A.; Yang, K.; Wang, M.; Liu, S.; Chintala, R.; Palm, T.; Zhao, H.; Peng, P.; Wu, D.; Zhang, Z.; Hua, J.; Hsieh, M. C.; Zhou, J.; Petti, G.; Li, X.; Janjua, A.; Mendez, M.; Liu, J.; Longley, C.; Zhang, Z.; Mehlig, M.; Borowski, V.; Viswanathan, M.; Filpula, D. Bioconjugate Chem. 2006, 17 (3), 618-630.
40. Yu, P. Z.; Qin, D.; Qin, G. H.; Fan, B.; Ma, G. H.; Su, Z. G. Process Biochem. 2009, 44 (12), 1340-1345.
41. Veronese, F. M.; Mero, A.; Caboi, F.; Sergi, M.; Marongiu, C.; Pasut, G. Bioconjugate Chem. 2007, 18 (6), 1824-1830.
42. Yang, C.; Lu, D.; Liu, Z. Biochemistry 2011, 50 (13), 2585-2593.
43. Acharya, S. A.; Acharya, V. N.; Kanika, N. D.; Tsai, A. G.; Intaglietta, M.; Manjula, B. N. Biochem. J. 2007, 405, 503-511.
44. Bhatnagar, B. S.; Martin, S. W.; Hodge, T. S.; Das, T. K.; Joseph, L.; Teagarden, D. L.; Shalaev, E. Y.; Suryanarayanan, R. J. Pharm. Sci. 2011, 100, 3062-3075.
45. Tattini, V.; Parra, D. F.; Polakiewicz, B.; Pitombo, R. N. M. Int. J. Pharm. 2005, 304 (1-2), 124-134.
46. Kubetzo, S.; Sarkar, C. A.; Plückthun, A. Mol. Pharmacol. 2005, 68 (5), 1439-1454.
47. Fishburn, C. S. J. Pharm. Sci. 2008, 97 (10), 4167-4183.
48. Young, M. A.; Malavalli, A.; Winslow, N.; Vandegriff, K. D.; Winslow, R. M. Transl. Res. 2007, 149 (6), 333-342.
49. Bendele, A.; Seely, J.; Richey, C.; Sennello, G.; Shopp, G. Toxicol. Sci. 1998, 42 (2), 152-157.
50. Webster, R.; Elliott, V.; Park, B. K.; Walker, D.; Hankin, M.; Taupin, P. In PEGylated protein drugs: Basic science and clinical applications; Veronese, F. M., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2009; pp 127-146.
51. Henics, T.; Wheatley, D. N. Biol. Cell 1999, 91 (7), 485-498.
52. Ishida, T.; Kiwada, H. Int. J. Pharm. 2008, 354 (1-2), 56-62.
53. Garratty, G. Transfusion Med. Rev. 2004, 18 (4), 245-256.
54. Garay, R. P.; El-Gewely, R.; Armstrong, J. K.; Garratty, G.; Richette, P. Expert Opin. Drug Delivery 2012, 9 (11), 1319-1323.
55. Xu, L.; Anchordoquy, T. J. Pharm. Sci. 2011, 100 (1), 38-52.
56. Singh, S. K. J. Pharm. Sci. 2011, 100 (2), 354-387.
57. Schlesinger, N.; Yasothan, U.; Kirkpatrick, P. Pegloticase. Nat. Rev. Drug Discovery 2011, 10 (1), 17-18.
58. Cimzia Prescribing Information.
59. Armstrong, J. K. In PEGylated protein drugs: Basic science and clinical applications; Veronese, F. M., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2009; pp 147-168.
60. Armstrong, J. K.; Hempel, G.; Koling, S.; Chan, L. S.; Fisher, T.; Meiselman, H. J.; Garratty, G. Cancer 2007, 110 (1), 103-111.
61. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. Angew. Chem., Int. Ed. 2010, 49 (36), 6288-6308.
62. Kontermann, R. E. Curr. Opin. Biotechnol. 2011, 22 (6), 868-876.
63. Dennis, M. S.; Zhang, M.; Meng, Y. G.; Kadkhodayan, M.; Kirchhofer, D.; Combs, D.; Damico, L. A. J. Biol. Chem. 2002, 277 (38), 35035-35043.
64. Sommermeyer, K.; Hildebrand, U.; Cech, F.; Pfitzer, E.; Henning, K.; Weidler, B. Starch 1992, 44 (5), 173.
65. Treib, J.; Baron, J. F.; Grauer, M. T.; Strauss, R. G. Intensive Care Med. 1999, 25, 258-268.
66. Brecher, M. E.; Owen, H. G.; Bandarenko, N. J. Clin. Apheresis 1997, 12, 146-153.
67. Jungheinrich, C.; Neff, T. Clin. Pharmacokinet. 2005, 44 (7), 681.
68. Orlando, Ph.D. Thesis, Justus Liebig Universität, Giessen, 2003.
69. Besheer, A.; Hertel, T. C.; Kressler, J.; Mäder, K.; Pietzsch, M. J. Pharm. Sci. 2009, 98 (11), 4420-4428.
70. Hey, T.; Knoller, H.; Vorstheim, P. In Therapeutic proteins: Strategies to modulate their plasma half-lives; Kontermann, R. E., Ed.; Wiley-VCH Verlag GmbH &Co.: Weinheim, Germany, 2012.
71. Gregoriadis, G.; Jain, S.; Papaioannou, I.; Laing, P. Int. J. Pharm. 2005, 300 (1-2), 125-130.
72. Lindhout, T.; Iqbal, U.; Willis, L. M.; Reid, A. N.; Li, J.; Liu, X.; Moreno, M.; Wakarchuk, W. W. Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (18), 7397-7402.
73. Jain, S.; Hreczuk-Hirst, D. H.; McCormack, B.; Mital, M.; Epenetos, A.; Laing, P.; Gregoriadis, G. Biochim. Biophys. Acta 2003, 1622 (1), 42-49.
74. Constantinou, A.; Epenetos, A. A.; Hreczuk-Hirst, D.; Jain, S.; Wright, M.; Chester, K. A.; Deonarain, M. P. Bioconjugate Chem. 2009, 20 (5), 924-931.
75. Constantinou, A.; Epenetos, A. A.; Hreczuk-Hirst, D.; Jain, S.; Deonarain, M. P. Bioconjugate Chem. 2008, 19 (3), 643-650.
76. Binder, U.; Skerra, A. In Therapeutic proteins: Strategies to modulate their plasma half-lives; Kontermann, R. E., Ed.; Wiley-VCH Verlag GmbH &Co. KGaA: Weinheim, Germany, 2012.
77. Schellenberger, V.; Wang, C. W.; Geething, N. C.; Spink, B. J.; Campbell, A.; To, W.; Scholle, M. D.; Yin, Y.; Yao, Y.; Bogin, O.; Cleland, J. L.; Silverman, J.; Stemmer, W. P. Nat. Biotechnol. 2009, 27 (12), 1186-1190.
78. Geething, N. C.; To, W.; Spink, B. J.; Scholle, M. D.; Wang, C. W.; Yin, Y.; Yao, Y.; Schellenberger, V.; Cleland, J. L.; Stemmer, W. P.; Silverman, J. PLoS One 2010, 5 (4), e10175.
79. Hayrinen, J.; Jennings, H.; Raff, H. V.; Rougon, G.; Hanai, N.; Gerardyschahn, R.; Finne, J. J. Infect. Dis. 1995, 171 (6), 1481-1490.
80. Astronomo, R. D.; Burton, D. R. Nat. Rev. Drug Discovery 2010, 9 (4), 308-324.